Drug Profile


Alternative Names: REGN-1500

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Developer Regeneron Pharmaceuticals
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action ANGPTL3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperlipoproteinaemia type IIa

Most Recent Events

  • 12 Nov 2016 Efficacy and safety data from a phase I trial in healthy volunteers presented at 89th Annual Scientific Sessions of the American Heart Association (AHA-2016)
  • 31 May 2016 Interim efficacy and adverse event data from a phase II trial in Homozygous Familial Hypercholestrolemia released by Regeneron Pharmaceuticals
  • 01 Sep 2015 Regeneron Pharmaceuticals completes a phase I trial in Metabolic disorders in USA (NCT02107872)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top